European Urology Focus
@eufocus.bsky.social
The aim of European Urology Focus (EU Focus) is to encompass the whole spectrum of urology. We embrace science that impacts the lifes of our patients. All that matters.
Efficacy of tx post-lenvatinib in RCC:
📉 Second-line therapy after first-line lenvatinib: ORR of 5% and median TTF of 5.8 months.
📊 Third-line therapy after second-line lenvatinib: ORR of 12% and median TTF of 2.8 months.
Definitely more effective late line tx needed🧐
📉 Second-line therapy after first-line lenvatinib: ORR of 5% and median TTF of 5.8 months.
📊 Third-line therapy after second-line lenvatinib: ORR of 12% and median TTF of 2.8 months.
Definitely more effective late line tx needed🧐
December 8, 2024 at 9:39 PM
Efficacy of tx post-lenvatinib in RCC:
📉 Second-line therapy after first-line lenvatinib: ORR of 5% and median TTF of 5.8 months.
📊 Third-line therapy after second-line lenvatinib: ORR of 12% and median TTF of 2.8 months.
Definitely more effective late line tx needed🧐
📉 Second-line therapy after first-line lenvatinib: ORR of 5% and median TTF of 5.8 months.
📊 Third-line therapy after second-line lenvatinib: ORR of 12% and median TTF of 2.8 months.
Definitely more effective late line tx needed🧐
New issue coming soon!
November 24, 2024 at 11:54 AM
New issue coming soon!
Radical cystectomy (RC) and trimodality therapy (TMT) yield comparable outcomes in muscle-invasive bladder cancer (MIBC)?
✨ 74.4% complete response with TMT.
🔄 23.1% recurrence rate in TMT-treated patients.
⚠️ 11.4% grade ≥3 toxicity for TMT.
Does this change your practice?
✨ 74.4% complete response with TMT.
🔄 23.1% recurrence rate in TMT-treated patients.
⚠️ 11.4% grade ≥3 toxicity for TMT.
Does this change your practice?
Redirecting
doi.org
November 23, 2024 at 12:04 PM
Radical cystectomy (RC) and trimodality therapy (TMT) yield comparable outcomes in muscle-invasive bladder cancer (MIBC)?
✨ 74.4% complete response with TMT.
🔄 23.1% recurrence rate in TMT-treated patients.
⚠️ 11.4% grade ≥3 toxicity for TMT.
Does this change your practice?
✨ 74.4% complete response with TMT.
🔄 23.1% recurrence rate in TMT-treated patients.
⚠️ 11.4% grade ≥3 toxicity for TMT.
Does this change your practice?
So excited to be on a new platform😃. Follow us to receive the latest news, most important new papers and insights from our editors.
November 22, 2024 at 7:15 PM
So excited to be on a new platform😃. Follow us to receive the latest news, most important new papers and insights from our editors.